Antiviral Drugs Treatment Market Size, Share, Analysis, Trends, Growth Report, 2030

Antiviral Drugs Treatment Market

Antiviral Drugs Treatment Market by Drug Class (DNA polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, and Others), by Type (Branded, and Generic), and Application (HIV, Hepatitis, Herpes, Influenza, and Others) – Global Industry Perspective Comprehensive Analysis and Forecast, 2020-2026

Category: Healthcare Report Format : PDF Pages: 134 Report Code: ZMR-5329 Published Date: Mar-2020 Status : Published
Market Size in 2019 Market Forecast in 2026 CAGR (in %) Base Year
USD 56.2 Billion USD 65.90 Billion 2.3% 2019

Antiviral Drugs Treatment Market

Antiviral Drugs Treatment Industry Prospective:

The Global Antiviral Drugs Treatment Market size was worth around USD 56.2 Billion in 2019 and is estimated to grow to about USD 65.90 Billion by 2026, with a compound annual growth rate (CAGR) of approximately 2.3% over the forecast period.

The report analyzes the Antiviral Drugs Treatment market’s drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the Antiviral Drugs Treatment market.

Antiviral Drugs Treatment Market: Overview

The report covers forecast and analysis for the Antiviral Drugs Treatment market on a global and regional level. The study provides historic data from 2016 to 2019 along with a forecast from 2020 to 2026 based on revenue (USD Billion). The study includes drivers and restraints for the Antiviral Drugs Treatment market along with the impact they have on the demand over the forecast period.

Additionally, the report includes the study of opportunities available in the Antiviral Drugs Treatment market on a global level. In order to give the users of this report a comprehensive view of the Antiviral Drugs Treatment market we have included a competitive landscape and analysis of Porter’s Five Forces model for the market.

The study encompasses a market attractiveness analysis, wherein Drug Class, Type, Application, and regional segments are benchmarked based on their market size, growth rate, and general attractiveness.

Viral infections have caused millions of human casualties worldwide across human history, prompting the production of antiviral drugs in urgent need. A new period of antiviral drug production began in June 1963, when the first antiviral medication, idoxuridine, was approved.

Antiviral drugs pertain to the class of medicines that have been used to treat viral infections including HIV, measles, hepatitis, and influenza. In general such medications are distributed in the form of vaccines. Moreover, most of these medications are used for common viral infections, while some (full-spectrum antiviral drugs) are effective against a large range of viruses.

Global Antiviral Drugs Treatment MarketRequest Free Sample

The study provides a decisive view of the Antiviral Drugs Treatment market by segmenting the market based on Drug Class, Type, Application, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2020 to 2026. Based on Drug Class, the market is segmented into DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, and Others.

Antiviral Drugs Treatment Market: Segmentation

Based on Type, the market is segmented into Branded and Generic. Based on Application, the market is segmented into HIV, Hepatitis, Herpes, Influenza, and Others. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Geographically speaking, North America dominated the Antiviral Drugs Treatment market with a share of about 37.22% in 2019. The key players’ presence in the region, the convenience of refined healthcare infrastructure, and cumulative awareness of viral diseases have led to increased demand for Antiviral drugs in the North American region.

Antiviral Drugs Treatment Market: Report Scope

Report Attributes Report Details
Report Name Antiviral Drugs Treatment Research Report
Market Size in 2019 USD 56.2 Billion
Market Forecast in 2026 USD 65.90 Billion
Growth Rate CAGR of 2.3%
Number of Pages 255
Forecast Units Value (USD Billion), and Volume (Units)
Key Companies Covered Gilead Sciences; F. Hoffmann-La Roche AG; GlaxoSmithKline plc; AbbVie; Merck & Co., Inc.; Johnson & Johnson Services, Inc.; Bristol-Myers Squibb Company; Cipla Inc.; Aurobindo Pharma; and Dr. Reddy’s Laboratories Ltd. & Co., Inc.
Segments Covered By Drug Class, By Type, By Application, And By Region
Regions Covered North America, Europe, Asia Pacific (APAC), Latin America, Middle East and Africa (MEA)
Base Year 2019
Historical Year 2016 to 2019
Forecast Year 2020 - 2026
Customization Scope Avail customized purchase options to meet your exact research needs. Request For Customization

Antiviral Drugs Treatment Market: Growth Factors

The growing occurrence of viral infections such as HIV, hepatitis, respiratory syncytial virus (RSV), and influenza is projected to boost the demand for antiviral drugs. Hepatitis B, for example, has caused about 987,000 deaths in 2017 according to data released by the WHO. In addition, in 2017 about 287 million patients were reported to have been infected with hepatitis B virus (HBV) infection. This is expected to drive the demand for efficient treatment solutions such as antiviral drugs.

Antiviral Drugs Treatment Market: Competitive Players

Key players within the global Antiviral Drugs Treatment market include 

  • Gilead Sciences
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • AbbVie
  • Merck & Co., Inc.
  • Johnson & Johnson Services. Inc.
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • Aurobindo Pharma
  • Dr. Reddy’s Laboratories Ltd. & Co. Inc
  • and others.

The report segments the global Antiviral Drugs Treatment market as follows:

Global Antiviral Drugs Treatment Market: Drug Class Segment Analysis

Global Antiviral Drugs Treatment Market: Type Segment Analysis

  • Branded
  • Generic

Global Antiviral Drugs Treatment Market: Application Segment Analysis

  • HIV
  • Hepatitis
  • Herpes
  • Influenza
  • Others

Global Antiviral Drugs Treatment Market: Regional Segment Analysis

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

Methodology

FrequentlyAsked Questions

Antiviral drug treatment involves the use of pharmaceuticals that are designed to target and prevent the growth and spread of viruses within the body. These treatments are also known as antiviral agents. Antiviral medications have been designed specifically to treat viral infections, which are caused by viruses, which are microscopic infectious agents that can cause a wide range of disorders.

The demand for antiviral medications is driven in a direct manner by the prevalence of viral illnesses such as HIV, influenza, and hepatitis, as well as new viruses (such as COVID-19). The growth of the market is aided by the rising prevalence of infectious diseases caused by viruses.

According to the report, global demand for Antiviral Drugs Treatment market was valued at approximately USD 56.2 billion in 2019, and is expected to generate revenue of around USD 65.90 billion by end of 2026, growing at a CAGR of around 2.3% between 2019 and 2026.

North America held largest revenue share of the global Antiviral Drugs Treatment market in 2019. This is attributed to the existence of key players in the region, accessibility of sophisticated healthcare infrastructure, and cumulative consciousness of viral diseases.

Major players in Antiviral Drugs Treatment market are Gilead Sciences; F. Hoffmann-La Roche AG; GlaxoSmithKline plc; AbbVie; Merck & Co., Inc.; Johnson & Johnson Services, Inc.; Bristol-Myers Squibb Company; Cipla Inc.; Aurobindo Pharma; and Dr. Reddy’s Laboratories Ltd. & Co., Inc.

Choose License Type

  • zion payment modes

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008

Contact #

US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • payment methods

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed